Biochemical Pharmacology volume 81, issue 3, P388-395 2011 DOI: 10.1016/j.bcp.2010.10.012 View full text
Wei-Chuan Chang, Kevan L. Hartshorn, Mitchell R. White, Patience Moyo, Ian C. Michelow, Henry Koziel, Bernard T. Kinane, Emmett V. Schmidt, Teizo Fujita, Kazue Takahashi

Abstract: AbstractMBL structurally contains a type II-like collagenous domain and a carbohydrate recognition domain (CRD). We have recently generated three novel recombinant chimeric lectins (RCL), in which varying length of collagenous domain of mannose-binding lectin (MBL) is replaced with that of L-ficolin (L-FCN). CRD of MBL is used for target recognition because it has a broad spectrum in pathogen recognition compared with L-FCN. Results of our study demonstrate that these RCLs are potent inhibitors of influenza A…

expand abstract